Abstract: Mitochondrially targeted antioxidants are used to prevent and treat severe inflammatory conditions including viral infection (such as COVID-19), systemic shock, trauma, burns, surgery associated with significant tissue damage, toxic damage, and damage associated with autoimmune reactions.

Abstract: Here are described SkQ compounds containing cations of various types: alkyl(triphenyl)phosphonium cation, quaternary ammonium cations, including pH-dependent and permanent cations of rhodamines, berberine and palmatine alkaloids.

Abstract: The invention relates to the manufacturing and use of pharmaceutical compositions of medicines (ophthalmic preparations) comprising a mitochondria-addressed antioxidant and a set of auxiliary substances providing effective treatment for ophthalmological diseases in humans and animals.

Abstract: The invention relates to the manufacturing and use of pharmaceutical compositions of medicines (ophthalmic preparations) comprising a mitochondria-addressed antioxidant and a set of auxiliary substances providing effective treatment for ophtalmological diseases in humans and animals.

Abstract: The present disclosure provides methods of preventing activation of neutrophils with mitochondrially targeted antioxidants. Also disclosed are methods of preventing or treating different inflammatory diseases and inflammation-related conditions with MTAs.

Abstract: The invention relates to the manufacturing and use of pharmaceutical compositions of medicines (ophthalmic preparations) comprising a mitochondria-addressed antioxidant and a set of auxiliary substances providing effective treatment for ophtalmological diseases in humans and animals.

Abstract: The present invention relates to pharmacology, medicine, ophthalmology, and, in particular, concerns a class of chemical compounds of structure (I) and also their solvates, isomers or prodrugs applicable when incorporated into pharmaceutical compositions also containing pharmaceutically acceptable carrier which can be useful for prophylaxis and treatment of different eye pathologies such as cataract and macular dystrophy.

Abstract: Provided are stable liquid and solid formulations of oxidized and reduced mitochondria-targeted antioxidants, and methods of their preparation and use.

Abstract: The invention provides timoquinone-based mitochondrially-targeted antioxidants (MTAs) and methods for their use.

Abstract: The invention relates to pharmacology, medicine and gerontology, in particular to a class of chemical structures (1) which can be used in compositions, in the form of geroprotectors, for extending the life time, decelerating, stopping or for reversing the process of the entirety of the organism's dysfunctions causing the mammal ageing and for preventing and treating particular senile diseases.

Abstract: This invention relates to biology and medicine and in particular it can be used in medicine for preparation of pharmaceutical composition that can accelerate wound healing by means of directed transport of biologically active substances (bioactive compounds) to the mitochondria, using hydrogen electrochemical potential in mitochondria. Besides, this invention relates to a certain method of influencing on the organism by means of said directed transport of required biologically active substances.

Abstract: The present disclosure provides methods of preventing activation of neutrophils with mitochondrially targeted anti-oxidants. Also disclosed are methods of preventing or treating different inflammatory diseases and inflammation-related conditions with MTAs.

Abstract: Disclosed is a method of treating a cancer on a mammal, comprising administering to the mammal in need thereof a therapeutically effective amount of a compound

Abstract: The invention relates to biology and medicine, in particular, can be used in medicine for preparation of a pharmaceutical composition for specific, self-regulating uncoupling of mitochondria. The invention may be useful in treatment of diseases and conditions associated with violation of cellular metabolism, in treatment of obesity including its pathological forms, as well as in treatment of diseases associated with increased formation of free radicals and reactive oxygen species. In addition, the invention may be used in biotechnology for stimulation of growth of yeast and microorganisms as well as for stimulation of development of tissues and organs of plant and animal origin.

Abstract: Provided are stable liquid and solid formulations of oxidized and reduced mitochondria-targeted antioxidants, and methods of their preparation and use.

Abstract: The present disclosure provides purified pharmaceutical preparations comprising oxidized SkQ1, wherein no individual impurity exceeds 1.5%, the total impurity content of the preparation does not exceed 4.

Abstract: Provided are stable liquid and solid formulations of oxidized and reduced mitochondria-targeted antioxidants, and methods of their preparation and use.

Abstract: Provided are stable liquid and solid formulations of oxidized and reduced mitochondria-targeted antioxidants, and methods of their preparation and use.

Abstract: The present invention relates to pharmacology, medicine, ophthalmology, and, in particular, concerns a class of chemical compounds of structure (I) and also their solvates, isomers or prodrugs applicable when incorporated into pharmaceutical compositions also containing pharmaceutically acceptable carrier which can be useful for prophylaxis and treatment of different eye pathologies such as cataract and macular dystrophy.

Abstract: The present invention relates to pharmacology, medicine, opthalmology, and, in particular, concerns a class of chemical compounds of structure (I) and also their solvates, isomers or prodrugs applicable when incorporated into pharmaceutical compositions also containing pharmaceutically acceptable carrier which can be useful for prophylaxis and treatment of different eye pathologies such as cataract and macular dystrophy.